Cipla shares jump 7% after at least six analyst upgrades on Q4 results, outlook

JPMorgan said Cipla’s upcoming pipeline, including launches of gVentolin, gAdvair, gSymbicort and select peptide products, as key growth drivers.

Leave a Reply

Your email address will not be published. Required fields are marked *